New HIV drug lipovirtide tested in early trial
NCT ID NCT05349968
First seen May 14, 2026 · Last updated May 14, 2026
Summary
This early-stage study tested a new injectable drug, Lipovirtide, in 24 people with HIV who were not taking any other HIV medications. The main goal was to check if the drug is safe and how the body processes it. Researchers also looked at whether it could lower the amount of virus in the blood. This is a first step in seeing if Lipovirtide might be a future treatment option for HIV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing You'an Hospital, Beijing Medical University
Beijing, China
Conditions
Explore the condition pages connected to this study.